Chitinase-1 inhibition attenuates airway hyperresponsiveness and type 2 airway inflammation in allergen-driven and TGF-β-driven murine models of airway remodeling
This study demonstrates that inhibiting Chitinase-1 with kasugamycin reduces airway hyperresponsiveness and type 2 inflammation in multiple murine models of airway remodeling, identifying CHIT1 as a promising therapeutic target despite the need for further research to confirm its impact on structural fibrosis.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Asthma is often thought of as a problem of breathing, but for many patients, the real trouble lies deeper in the structure of the lungs. Over time, chronic inflammation can cause the airways to thicken and stiffen, a process known as remodeling. This scarring makes it difficult for air to flow freely and, crucially, makes the damage hard to reverse. While current medicines can calm the swelling and open the airways temporarily, none are proven to stop or undo this structural hardening. Scientists have long suspected that a specific family of enzymes, which normally help the body break down the tough outer shells of fungi and insects, might be playing a hidden role in this scarring. In the lungs, these enzymes can sometimes go into overdrive, triggering signals that tell the body to lay down more scar tissue. The question researchers have been asking is whether stopping these enzymes could protect the lungs from becoming stiff and narrow.
In a new study, scientists at Yonsei University in South Korea tested this idea using a specific drug called kasugamycin. This substance, originally known as an agricultural antibiotic, was recently discovered to block the activity of one of these enzymes, called chitinase-1. The researchers wanted to see if blocking this enzyme could improve the function of the airways and reduce the inflammation that leads to scarring. They did not just look at one type of lung problem; they tested the drug in three different scenarios within mice. In one scenario, the mice were exposed to house dust mites, a common trigger for human allergies. In the other two scenarios, the mice were genetically programmed to produce high levels of a growth factor known to cause fibrosis, or scarring, in the lungs. This allowed the team to see if the drug worked whether the problem started with an allergy or with a direct signal to build scar tissue.
The results were encouraging for the function of the lungs. In all three groups of mice, those treated with the drug showed reduced airway hyperresponsiveness. This is a technical term for the tendency of the airways to squeeze shut too easily when exposed to irritants. When the researchers measured how much the airways narrowed in response to a mist, the treated mice held their shape better than the untreated ones, a trend observed consistently across the different models. The drug also reduced the number of immune cells flooding the lungs. In the allergic mice, the levels of specific inflammatory chemicals, known as type 2 cytokines, dropped dramatically, returning to levels similar to healthy, untreated mice. This suggests that the drug successfully quieted the immune system's overreaction.
The study also looked at the genes that control how the lungs build scar tissue. In the mice treated with the drug, the instructions for making collagen and other structural proteins were turned down compared to the untreated mice. However, the researchers were careful to note that while the direction of this change was consistent, the study was not large enough to prove that the amount of actual scar tissue in the lungs was reduced. The number of animals used in each group was small, meaning that while the trend points toward less scarring, the evidence is not yet strong enough to claim the drug reverses existing fibrosis. Furthermore, the team did not measure whether the drug actually blocked the enzyme inside the lungs of these specific mice, so they cannot be certain that the enzyme was the only thing the drug was affecting.
Despite these limitations, the findings offer a clear new path for understanding asthma. The study provides the first physiologic evidence that inhibiting chitinase-1 can change how airways function, though the researchers emphasize that because they could not verify that the drug actually engaged its target in these specific animals, the mechanism remains undetermined and an effect unrelated to the enzyme cannot be excluded. The effect was seen in both male and female mice, at different doses, and whether the drug was given before the damage started or after it was already underway. This consistency suggests that the enzyme is a robust target for future therapies. The researchers conclude that while this drug is not yet a proven cure for lung scarring, it provides the first solid evidence that stopping this specific enzyme can change the way airways function, pending confirmation of the mechanism. The next step, they say, is to run larger, more detailed studies to confirm that the drug truly engages its target and to measure exactly how much scar tissue it can prevent or remove. Until then, the work stands as a promising hint that the structural damage of asthma might one day be stopped in its tracks.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.